Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2024-09-25 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva fait un point sur ses activités et publie ses résultats financiers non audités du premier semestre 2024
Earnings Release Classification · 99% confidence The document is titled "Inventiva fait un point sur ses activités et publie ses résultats financiers non audités du premier semestre 2024" (Inventiva provides an update on its activities and publishes its unaudited financial results for the first half of 2024). It contains a detailed table of key financial results (Chiffre d'affaires, Résultat Net, etc.) comparing the first half of 2024 (30 juin 2024) with previous periods, and discusses R&D progress and cash flow. This structure—a comprehensive financial review for a period shorter than a year (six months)—is characteristic of an Interim/Quarterly Report. It is not just an Earnings Release (ER) as it contains detailed financial statements and management discussion, nor is it the full Annual Report (10-K). Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2024
2024-09-25 French
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the six-month period ended June 30, 2024. It includes detailed financial statements (income statement, cash flow analysis), management's discussion and analysis of financial results, and updates on clinical programs. It is not a mere announcement or a short summary, but a substantive interim financial report. H1 2024
2024-09-25 English
Franchissement de seuil
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing a threshold (Article L. 233-7 of the Commercial Code)'. It explicitly states that UBS Group AG crossed below the 5% threshold of INVENTIVA's capital on August 23, 2024. This type of filing, reporting changes in significant share ownership crossing regulatory thresholds, directly corresponds to the Major Shareholding Notification category (MRQ). The document is short and contains specific regulatory reporting details, confirming it is a direct filing rather than an announcement of a filing.
2024-08-30 French
Inventiva publie ses informations financières préliminaires du premier semestre 2024¹
Earnings Release Classification · 100% confidence The document is titled "Inventiva publie ses informations financières préliminaires du premier semestre 2024" (Inventiva publishes its preliminary financial information for the first half of 2024). It contains key financial metrics (cash, R&D expenses, revenue) for the first half of 2024 compared to 2023, and discusses financing activities (royalty certificates issuance). This content structure—preliminary financial highlights for a specific interim period (H1 2024)—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it explicitly states 'informations financières préliminaires' and focuses on key highlights rather than being a comprehensive, audited report, it aligns best with the definition of an Earnings Release (ER). The document also mentions the next financial event: 'Résultats financiers du premier semestre 2024 : mercredi 25 septembre 2024', suggesting this document is the initial announcement of those results. H1 2024
2024-07-31 French
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
Earnings Release Classification · 99% confidence The document is titled "Inventiva Reports Preliminary 2024 First-Half Financial Information" and contains detailed preliminary financial metrics for the first half of 2024 (H1 2024), including cash balances, revenues, R&D expenses, and financing activities. It explicitly states these are preliminary, non-audited financial results. This content structure—a press release summarizing key financial figures for a specific interim period (half-year)—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses on preliminary results and cash position rather than being a comprehensive, fully audited report, it aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical financial results (key highlights). Although it covers a half-year period, the format is a press release announcing highlights, making ER a stronger fit than the comprehensive IR code, which usually implies the full filing document. H1 2024
2024-07-31 English
Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor
Regulatory Filings Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) in French and contains standard press release formatting, including a headline, bullet points summarizing key news, a dateline (Daix, France, Long Island City, USA, July 25, 2024), quotes from management, and contact information. The core content announces that the Japanese Patent Office granted a patent for lanifibranor. This type of announcement, which is a formal communication of a specific, material event (a patent grant) to the public and investors, fits best under the general category for regulatory announcements or news releases that aren't specific financial reports (like 10-K, ER, or IR). Since it is a specific, non-financial regulatory/corporate update (Intellectual Property news), and not a general regulatory filing fallback (RNS), the most appropriate category among the provided options for a press release detailing corporate news, especially IP news, is often RNS (Regulatory Filings) if a more specific category like 'IP' (which is not an option) is unavailable. However, given the nature of the announcement (a specific corporate event update via press release), and looking at the definitions, RNS is the designated fallback for miscellaneous regulatory announcements. Since there is no specific 'Intellectual Property Announcement' code, RNS serves as the best fit for a general corporate news release that isn't a financial report or management change.
2024-07-25 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.